Table 2. . Comparison between demographic and laboratory variables in different ITGA4 fold change categories of chronic lymphocytic leukemia patients.
| Variables |
ITGA4 <0.5-fold change CLL patients (n = 20) |
ITGA4 >1.5-fold change CLL patients (n = 38) |
p-value |
|---|---|---|---|
| Gender – Males, n (%) – Females, n (%) |
14 (70) 6 (30) |
20 (52.6) 18 (47.4) |
0.250 (NS) |
| Age (years), (mean ± SE) | 58.2 ± 2.9 | 57.3 ± 1.7 | 0.797 (NS) |
| B2M (µg/ml), (mean ± SE) | 4.7 ± 0.69 | 5.8 ± 0.55 | 0.268 (NS) |
| ITGA4 protein expression %(mean ± SE) | 4.4 ± 2.3 | 20.8 ± 4.8 | 0.001‡ |
| CD38 % (mean ± SE) | 21.6 ± 7.3 | 13.9 ± 2.7 | 0.334 (NS) |
| ZAP-70 % (mean ± SE) | 1.9 ± 1.3 | 5.1 ± 2.2 | 0.353 (NS) |
| Trisomy12 % (mean ± SE) | 2.14 ± 0.376 | 9.08 ± 3.3 | 0.046† |
| Del17p % (mean ± SE) | 3.14 ± 0.619 | 2.58 ± 0.3 | 0.358 (NS) |
| Del11q % (mean ± SE) | 16.86 ± 8.5 | 7.0 ± 3.3 | 0.297 (NS) |
| Del13q14 % (mean ± SE) | 31.7 ± 9.3 | 7.9 ± 3.7 | 0.079 (NS) |
| ITGA4 gene methylation | |||
| – CpG site-1 % (mean ± SE) | 31.1 ± 2.0 | 25.4 ± 1.4 | 0.029† |
| – CpG site-2 % (mean ± SE) | 3.9 ± 0.5 | 2.5 ± 0.157 | 0.01† |
| – CpG site-3 % (mean ± SE) | 4.3 ± 0.57 | 3.4 ± 0.25 | 0.088 (NS) |
| – CpG site-4 % (mean ± SE) | 8.1 ± 0.76 | 7.3 ± 0.3200 | 0.347 (NS) |
†
p < 0.05 is considered significant.
‡
p < 0.01 is considered highly significant.
CLL: Chronic lymphocytic leukemia; SE: Standard error; NS: Non-significant.